Decreased plasma cysteinylglycine and taurine levels in branch retinal Vein Occlusion

Ophthalmic Research

Volumn 43, Issue 1, 2009, Pages 26-32

  Pinna, Antonio ^a   Zinellu, Angelo ^b   Franconi, Flavia ^c   Solinas, Giuliana ^a   Carru, Ciriaco ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b Institute of Clinical Biochemistry

^c Department of Pharmacology   (Italy)

Author keywords

Branch retinal vein occlusion; Cysteine; Cysteinylglycine; Glutamylcysteine; Glutathione; Homocysteine; Laser induced fluorescence capillary electrophoresis; Taurine

Indexed keywords

CYSTEINE; CYSTEINYLGLYCINE; GLUTAMYLCYSTEINE; GLUTATHIONE; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFUR AMINO ACID; TAURINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANK SUM TEST; RISK FACTOR; STUDENT T TEST;

AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYSTEINE; DIPEPTIDES; ELECTROPHORESIS, CAPILLARY; FEMALE; GLUTATHIONE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RISK FACTORS; TAURINE;

EID: 70349889003     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000246575     Document Type: Article

References (54)

1. Fekrat S, Finkelstein D: Branch retinal vein occlusion; in Ryan SJ (ed): Retina, ed 3. St. Louis, Mosby, 2001, vol 2, pp 1376-1381.
2. Klein R, Moss SE, Meuer SM, Klein BE: The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008; 126: 513-518. (Pubitemid 351549845)
3. Seitz R: The Retinal Vessels, ed 1. Stuttgart, Enke, 1962, vol 40.
4. Kumar B, Yu D, Morgan WH, Barry CJ, Constable IJ, MacAllister IL: The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology 1998; 105: 424-427.
5. Eye Disease Case-Control Study Group: Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993; 116: 286-296.
6. Lip PL, Blann AD, Jones AF, Lip GYH: Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye 1998; 12: 245-251.
7. Finkelstein JD: Methionine metabolism in mammals. J Nutr Biochem 1990; 1: 228-237.
8. Worden JA, Stipanuk MH: A comparison by species, age and sex of cysteinesulfinate decarboxylase activity and taurine concentration in liver and brain of animals. Comp Biochem Physiol 1985; 82: 233-239.
9. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057.
10. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050. (Pubitemid 128753793)
11. Jacob N, Bruckert E, Giral P, Foglietti MJ, Turpin G: Cysteine is a cardiovascular risk factor in hyperlipidemic patients. Atherosclerosis 1999; 146: 53-59.
12. El-Khairy L, Ueland PM, Refsum H, Graham IM, Vollset SE: Plasma total cysteine as a risk factor for vascular disease. Circulation 2001; 103: 2544-2549.
13. Heinecke JW, Rosen H, Suzuki LA, Chait A: The role of sulfur-containing amino acids in superoxide production and modification of low-density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-10103.
14. Kugiyama K, Ohgushi M, Motoyama T, et al.: Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation. Circulation 1998; 97: 2299-2301.
15. Lapenna D, de Gioia S, Ciofani G, et al.: Glutathione- related antioxidant defenses in human atherosclerotic plaques. Circulation 1998; 97: 1930-1934.
16. Morrison JA, Jacobsen DW, Sprecher DL, Robinson K, Khoury P, Daniels SR: Serum glutathione in adolescent males predicts parental coronary heart disease. Circulation 1999; 100: 2244-2247.
17. Zinellu A, Zinellu E, Sotgia S, et al.: Factors affecting S-homocysteinylation of LDL apoprotein B. Clin Chem 2006; 52: 2054-2059.
18. McCully KS, Wilson RB: Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22: 215-227.
19. Ferretti G, Bacchetti T, Moroni C, Vignini A, Nanetti L, Curatola G: Effect of homocysteinylation of low-density lipoprotein on lipid peroxidation of human endothelial cells. J Cell Biochem 2004; 92: 351-360.
20. Huxtable RJ: Physiological actions of taurine. Physiol Rev 1992; 72: 101-163.
21. Murakami S, Kondo Y, Sakurai T, Kitajima H, Nagate T: Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis 2002; 163: 79-87.
22. Cahill M, Karabatzaki M, Meleady R, et al.: Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000; 84: 154-157.
23. Martin SC, Rauz S, Marr JE, Martin N, Jones AF, Dodson PM: Plasma total homocysteine and retinal vascular disease. Eye 2000; 14: 590-593.
24. Weger M, Stanger O, Deutschmann H, et al.: Hyperhomocysteinemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion. Ophthalmology 2002; 109: 1105-1109. (Pubitemid 34546918)
25. Cahill MT, Stinnett SS, Fekrat S: Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136: 1136-1150.
26. McGimpsey SJ, Woodside JV, Bamford L, et al.: Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci 2005; 46: 4712-4716.
27. Pinna A, Carru C, Zinellu A, Dore S, Deiana L, Carta F: Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest Ophthalmol Vis Sci 2006; 47: 4067-4071.
28. Zinellu A, Pinna A, Zinellu E, et al.: Highthroughput capillary electrophoresis method for plasma cysteinylglycine measurement: evidences for a clinical application. Amino Acids 2007; 34: 69-74.
29. Zinellu A, Carru C, Galistu F, et al.: N-methyl- D-glucamine improves the laser-induced fluorescence capillary electrophoresis performance in the total plasma thiols measurement. Electrophoresis 2003; 24: 2796-2804.
30. Zinellu A, Sotgia S, Scanu B, et al.: Taurine determination by capillary electrophoresis with laser-induced fluorescence detection: from clinical field to quality food applications. Amino Acids DOI: 10.1007/s00726- 007-0022-25
31. Clayton D, Hills M: Statistical Models in Epidemiology. Oxford, Oxford University Press, 1993.
32. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ: Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A metaanalysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-1026.
33. Nygard O, Refsum H, Ueland PM, Vollset SE: Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study: Am J Clin Nutr 1998; 67: 263-270. (Pubitemid 28076718)
34. Stamler JS, Slivka A: Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 1996; 54: 1-30.
35. Nishiuch Y, Sasaki M, Nakayasu M, Oikawa A: Cytotoxicity of cysteine in culture media. In Vitro 1976; 12: 635-638.
36. Dudman NP, Hicks C, Wang J, Wilken DE: Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 1991; 91: 77-83.
37. Lakshminarayanan V, Lewallen M, Frangogiannis NG, et al.: Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol 2001; 159: 1301-1311.
38. Heinecke JW, Rosen H, Suzuki LA, Chait A: The role of sulfur-containing amino acids in superoxide production and modification of low-density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-10103.
39. Hogg N: The effect of cysteine on the autooxidation of homocysteine. Free Radic Biol Med 1999; 27: 28-33.
40. Verhoef P, Stampfer MJ, Buring JE, et al.: Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996; 143: 845-849.
41. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T: Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989; 79: 139-146.
42. Mansoor MA, Bergmark C, Svardal AM, Lonning PE, Ueland PM: Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995; 15: 232-240.
43. Kugiyama K, Ohgushi M, Motoyama T, et al.: Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation. Circulation 1998; 97: 2299-2301.
44. Lapenna D, de Gioia S, Ciofani G, et al.: Glutathione- related antioxidant defenses in human atherosclerotic plaques. Circulation 1998; 97: 1930-1934.
45. Morrison JA, Jacobsen DW, Sprecher DL, Robinson K, Khoury P, Daniels SR: Serum glutathione in adolescent males predicts parental coronary heart disease. Circulation 1999; 100: 2244-2247.
46. Hayes K, Rabin A, Berson E: An ultrastructure study of nutritionally induced and reversed retinal degeneration in cats. Am J Pathol 1975; 78: 505-509.
47. Uma SM, Satapathy M, Sitaramayya A: Decreased plasma taurine levels in retinitis pigmentosa. Biochem Med 1983; 30: 49-52.
48. Benini G, Marconcini C, Wirth A, Montagnoli G: Is taurine a marker for retinitis pigmentosa? Ophthalmologica 1988; 197: 130-135.
49. Pasantes-Morales H, Quiroz H, Quesada O: Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. Metab Brain Dis 2002; 17: 183-197.
50. Murakami S, Yamagishi I, Asami Y, et al.: Hypolipidemic effect of taurine in strokeprone spontaneously hypertensive rats. Pharmacology 1996; 52: 303-313.
51. Murakami S, Kondo-Ohta Y, Tomisawa K: Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet. Life Sci 1999; 64: 83-91.
52. Tan B, Jiang DJ, Huang H, et al.: Taurine protects against low-density lipoproteininduced endothelial dysfunction by the DDAH/ADMA pathway. Vascul Pharmacol 2007; 46: 338-345.
53. Dodson PM, Kubicki AJ, Taylor KG, Kritzinger EE: Medical conditions underlying recurrence of retinal vein occlusion. Br J Ophthalmol 1985; 69: 493-496.
54. Weger M, Renner W, Steinbrugger I, et al.: Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. Ophthalmology 2005; 112: 1910-1915. (Pubitemid 41551918)